Complete response of gastrointestinal stromal tumor liver metastases to regorafenib
Imatinib, sunitinib, and regorafenib show high disease control rates for metastatic or unresectable gastrointestinal stromal tumor. However, partial response rates are low, and complete response to regorafenib had not been reported. Our case was an 81-year-old woman who underwent partial gastrectomy...
Gespeichert in:
| Veröffentlicht in: | International cancer conference journal 2015-07, Vol.4 (3), p.167-171 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 171 |
|---|---|
| container_issue | 3 |
| container_start_page | 167 |
| container_title | International cancer conference journal |
| container_volume | 4 |
| creator | Kitayama, Hiromitsu Hirayama, Michiaki Sugiyama, Junko Kondo, Tomohiro Oyamada, Yumiko Takahashi, Sho Tsuji, Yasushi |
| description | Imatinib, sunitinib, and regorafenib show high disease control rates for metastatic or unresectable gastrointestinal stromal tumor. However, partial response rates are low, and complete response to regorafenib had not been reported. Our case was an 81-year-old woman who underwent partial gastrectomy for an extremely large high risk gastrointestinal stromal tumor. Adjuvant imatinib caused intolerable adverse effects. One year after the surgery, local recurrence was diagnosed and sunitinib was started. Sunitinib also caused severe adverse effects. However, long-term disease control for 39 months was achieved with adequate dose reduction. After that period, the local recurrence started to grow rapidly, and the patient underwent total gastrectomy and distal pancreatectomy with excisions of nearby seeding nodules. Six months after the second operation, two liver metastasis nodules and one peritoneal metastasis nodule were found. We started regorafenib at standard dose. One month after the start of regorafenib treatment, the dose was reduced as follows: 2 weeks administration of 80 mg per day followed by 2 weeks drug holiday, due to intolerable adverse effects. The evaluation computed tomography and 18F-Fluorodeoxyglucose positron emission tomography could confirm complete response of her liver metastases. Even low dose regorafenib could maintain complete response for 10 months with only mild adverse effect. We report the first case of clinical complete response by regorafenib against liver metastases of gastrointestinal stromal tumor with intolerance to imatinib and refractory to sunitinib. |
| doi_str_mv | 10.1007/s13691-014-0192-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2920702432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920702432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c246t-9e954d53d78da6b1762d0a048fd34d45cdee206b52100c27ae8f7e1164a6b7803</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMouOj-AG8Bz9XJR5P2KItfsOBBPYdsM126tE1NsoL_3pQKevEwzAw87_DOS8gVgxsGoG8jE6pmBTCZq-aFPCErPg-CVeL0z3xO1jEeAICDrKFSK_K68cPUY0IaME5-jEh9S_c2puC7MWFM3Wh7Oq9D7uk4-ED77hMDHTBlzEaMNPks3_tgWxy73SU5a20fcf3TL8j7w_3b5qnYvjw-b-62RcOlSkWNdSldKZyunFU7phV3YEFWrRPSybJxiBzUruT5yYZri1WrkTElM60rEBfkerk7Bf9xzFbNwR9DthsNrzlo4FLwTLGFaoKPMWBrptANNnwZBmaOzyzxmRyfmeMzMmv4oomZHfcYfi__L_oGsetzDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920702432</pqid></control><display><type>article</type><title>Complete response of gastrointestinal stromal tumor liver metastases to regorafenib</title><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Kitayama, Hiromitsu ; Hirayama, Michiaki ; Sugiyama, Junko ; Kondo, Tomohiro ; Oyamada, Yumiko ; Takahashi, Sho ; Tsuji, Yasushi</creator><creatorcontrib>Kitayama, Hiromitsu ; Hirayama, Michiaki ; Sugiyama, Junko ; Kondo, Tomohiro ; Oyamada, Yumiko ; Takahashi, Sho ; Tsuji, Yasushi</creatorcontrib><description>Imatinib, sunitinib, and regorafenib show high disease control rates for metastatic or unresectable gastrointestinal stromal tumor. However, partial response rates are low, and complete response to regorafenib had not been reported. Our case was an 81-year-old woman who underwent partial gastrectomy for an extremely large high risk gastrointestinal stromal tumor. Adjuvant imatinib caused intolerable adverse effects. One year after the surgery, local recurrence was diagnosed and sunitinib was started. Sunitinib also caused severe adverse effects. However, long-term disease control for 39 months was achieved with adequate dose reduction. After that period, the local recurrence started to grow rapidly, and the patient underwent total gastrectomy and distal pancreatectomy with excisions of nearby seeding nodules. Six months after the second operation, two liver metastasis nodules and one peritoneal metastasis nodule were found. We started regorafenib at standard dose. One month after the start of regorafenib treatment, the dose was reduced as follows: 2 weeks administration of 80 mg per day followed by 2 weeks drug holiday, due to intolerable adverse effects. The evaluation computed tomography and 18F-Fluorodeoxyglucose positron emission tomography could confirm complete response of her liver metastases. Even low dose regorafenib could maintain complete response for 10 months with only mild adverse effect. We report the first case of clinical complete response by regorafenib against liver metastases of gastrointestinal stromal tumor with intolerance to imatinib and refractory to sunitinib.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-014-0192-4</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Biomarkers ; Case Report ; Computed tomography ; Conflicts of interest ; Disease control ; Drug dosages ; Gastrectomy ; Gastrointestinal cancer ; Gastrointestinal surgery ; Growth factors ; Imatinib ; Inhibitor drugs ; Kinases ; Liver ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Mutation ; Nodules ; Oncology ; Patients ; Positron emission tomography ; Side effects ; Surgical Oncology ; Targeted cancer therapy ; Tomography ; Tumors</subject><ispartof>International cancer conference journal, 2015-07, Vol.4 (3), p.167-171</ispartof><rights>The Japan Society of Clinical Oncology 2014</rights><rights>The Japan Society of Clinical Oncology 2014.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c246t-9e954d53d78da6b1762d0a048fd34d45cdee206b52100c27ae8f7e1164a6b7803</citedby><cites>FETCH-LOGICAL-c246t-9e954d53d78da6b1762d0a048fd34d45cdee206b52100c27ae8f7e1164a6b7803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13691-014-0192-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2920702432?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,21369,21370,27905,27906,33511,33725,41469,42538,43640,43786,51300,64364,64368,72218</link.rule.ids></links><search><creatorcontrib>Kitayama, Hiromitsu</creatorcontrib><creatorcontrib>Hirayama, Michiaki</creatorcontrib><creatorcontrib>Sugiyama, Junko</creatorcontrib><creatorcontrib>Kondo, Tomohiro</creatorcontrib><creatorcontrib>Oyamada, Yumiko</creatorcontrib><creatorcontrib>Takahashi, Sho</creatorcontrib><creatorcontrib>Tsuji, Yasushi</creatorcontrib><title>Complete response of gastrointestinal stromal tumor liver metastases to regorafenib</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><description>Imatinib, sunitinib, and regorafenib show high disease control rates for metastatic or unresectable gastrointestinal stromal tumor. However, partial response rates are low, and complete response to regorafenib had not been reported. Our case was an 81-year-old woman who underwent partial gastrectomy for an extremely large high risk gastrointestinal stromal tumor. Adjuvant imatinib caused intolerable adverse effects. One year after the surgery, local recurrence was diagnosed and sunitinib was started. Sunitinib also caused severe adverse effects. However, long-term disease control for 39 months was achieved with adequate dose reduction. After that period, the local recurrence started to grow rapidly, and the patient underwent total gastrectomy and distal pancreatectomy with excisions of nearby seeding nodules. Six months after the second operation, two liver metastasis nodules and one peritoneal metastasis nodule were found. We started regorafenib at standard dose. One month after the start of regorafenib treatment, the dose was reduced as follows: 2 weeks administration of 80 mg per day followed by 2 weeks drug holiday, due to intolerable adverse effects. The evaluation computed tomography and 18F-Fluorodeoxyglucose positron emission tomography could confirm complete response of her liver metastases. Even low dose regorafenib could maintain complete response for 10 months with only mild adverse effect. We report the first case of clinical complete response by regorafenib against liver metastases of gastrointestinal stromal tumor with intolerance to imatinib and refractory to sunitinib.</description><subject>Biomarkers</subject><subject>Case Report</subject><subject>Computed tomography</subject><subject>Conflicts of interest</subject><subject>Disease control</subject><subject>Drug dosages</subject><subject>Gastrectomy</subject><subject>Gastrointestinal cancer</subject><subject>Gastrointestinal surgery</subject><subject>Growth factors</subject><subject>Imatinib</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Liver</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Nodules</subject><subject>Oncology</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Side effects</subject><subject>Surgical Oncology</subject><subject>Targeted cancer therapy</subject><subject>Tomography</subject><subject>Tumors</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LxDAQhoMouOj-AG8Bz9XJR5P2KItfsOBBPYdsM126tE1NsoL_3pQKevEwzAw87_DOS8gVgxsGoG8jE6pmBTCZq-aFPCErPg-CVeL0z3xO1jEeAICDrKFSK_K68cPUY0IaME5-jEh9S_c2puC7MWFM3Wh7Oq9D7uk4-ED77hMDHTBlzEaMNPks3_tgWxy73SU5a20fcf3TL8j7w_3b5qnYvjw-b-62RcOlSkWNdSldKZyunFU7phV3YEFWrRPSybJxiBzUruT5yYZri1WrkTElM60rEBfkerk7Bf9xzFbNwR9DthsNrzlo4FLwTLGFaoKPMWBrptANNnwZBmaOzyzxmRyfmeMzMmv4oomZHfcYfi__L_oGsetzDA</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Kitayama, Hiromitsu</creator><creator>Hirayama, Michiaki</creator><creator>Sugiyama, Junko</creator><creator>Kondo, Tomohiro</creator><creator>Oyamada, Yumiko</creator><creator>Takahashi, Sho</creator><creator>Tsuji, Yasushi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20150701</creationdate><title>Complete response of gastrointestinal stromal tumor liver metastases to regorafenib</title><author>Kitayama, Hiromitsu ; Hirayama, Michiaki ; Sugiyama, Junko ; Kondo, Tomohiro ; Oyamada, Yumiko ; Takahashi, Sho ; Tsuji, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c246t-9e954d53d78da6b1762d0a048fd34d45cdee206b52100c27ae8f7e1164a6b7803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomarkers</topic><topic>Case Report</topic><topic>Computed tomography</topic><topic>Conflicts of interest</topic><topic>Disease control</topic><topic>Drug dosages</topic><topic>Gastrectomy</topic><topic>Gastrointestinal cancer</topic><topic>Gastrointestinal surgery</topic><topic>Growth factors</topic><topic>Imatinib</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Liver</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Nodules</topic><topic>Oncology</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Side effects</topic><topic>Surgical Oncology</topic><topic>Targeted cancer therapy</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitayama, Hiromitsu</creatorcontrib><creatorcontrib>Hirayama, Michiaki</creatorcontrib><creatorcontrib>Sugiyama, Junko</creatorcontrib><creatorcontrib>Kondo, Tomohiro</creatorcontrib><creatorcontrib>Oyamada, Yumiko</creatorcontrib><creatorcontrib>Takahashi, Sho</creatorcontrib><creatorcontrib>Tsuji, Yasushi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitayama, Hiromitsu</au><au>Hirayama, Michiaki</au><au>Sugiyama, Junko</au><au>Kondo, Tomohiro</au><au>Oyamada, Yumiko</au><au>Takahashi, Sho</au><au>Tsuji, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete response of gastrointestinal stromal tumor liver metastases to regorafenib</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><date>2015-07-01</date><risdate>2015</risdate><volume>4</volume><issue>3</issue><spage>167</spage><epage>171</epage><pages>167-171</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>Imatinib, sunitinib, and regorafenib show high disease control rates for metastatic or unresectable gastrointestinal stromal tumor. However, partial response rates are low, and complete response to regorafenib had not been reported. Our case was an 81-year-old woman who underwent partial gastrectomy for an extremely large high risk gastrointestinal stromal tumor. Adjuvant imatinib caused intolerable adverse effects. One year after the surgery, local recurrence was diagnosed and sunitinib was started. Sunitinib also caused severe adverse effects. However, long-term disease control for 39 months was achieved with adequate dose reduction. After that period, the local recurrence started to grow rapidly, and the patient underwent total gastrectomy and distal pancreatectomy with excisions of nearby seeding nodules. Six months after the second operation, two liver metastasis nodules and one peritoneal metastasis nodule were found. We started regorafenib at standard dose. One month after the start of regorafenib treatment, the dose was reduced as follows: 2 weeks administration of 80 mg per day followed by 2 weeks drug holiday, due to intolerable adverse effects. The evaluation computed tomography and 18F-Fluorodeoxyglucose positron emission tomography could confirm complete response of her liver metastases. Even low dose regorafenib could maintain complete response for 10 months with only mild adverse effect. We report the first case of clinical complete response by regorafenib against liver metastases of gastrointestinal stromal tumor with intolerance to imatinib and refractory to sunitinib.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><doi>10.1007/s13691-014-0192-4</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-3183 |
| ispartof | International cancer conference journal, 2015-07, Vol.4 (3), p.167-171 |
| issn | 2192-3183 2192-3183 |
| language | eng |
| recordid | cdi_proquest_journals_2920702432 |
| source | ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; SpringerLink Journals - AutoHoldings; ProQuest Central |
| subjects | Biomarkers Case Report Computed tomography Conflicts of interest Disease control Drug dosages Gastrectomy Gastrointestinal cancer Gastrointestinal surgery Growth factors Imatinib Inhibitor drugs Kinases Liver Medicine Medicine & Public Health Metastases Metastasis Mutation Nodules Oncology Patients Positron emission tomography Side effects Surgical Oncology Targeted cancer therapy Tomography Tumors |
| title | Complete response of gastrointestinal stromal tumor liver metastases to regorafenib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T22%3A37%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20response%20of%20gastrointestinal%20stromal%20tumor%20liver%20metastases%20to%20regorafenib&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Kitayama,%20Hiromitsu&rft.date=2015-07-01&rft.volume=4&rft.issue=3&rft.spage=167&rft.epage=171&rft.pages=167-171&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-014-0192-4&rft_dat=%3Cproquest_cross%3E2920702432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2920702432&rft_id=info:pmid/&rfr_iscdi=true |